Home / Technology / 10 deadly coronavirus patients receive Israeli drug discharged from the hospital in one day

10 deadly coronavirus patients receive Israeli drug discharged from the hospital in one day



MesenCure Development Entrepreneurs (from right): Dr. Dror Ben David, Dr. Shai Meretzki and Tomer Bronstein.MesenCure Development Entrepreneurs (from right): Dr. Dror Ben David, Dr. Shai Meretzki and Tomer Bronstein.Bonus’ MesenCure contains activated Mesenchymal Stromal Cells (MSCs) isolated from healthy donor adipose tissue. found to reduce inflammation Promotes the regeneration of diseased lung tissue. and relieve respiratory and other symptoms In Patients Suffering from Life ̵
1; Breathing Difficulty Threatened by COVID-19 “So far, the results of treatment with MesenCure have been extremely impressive. and better than the outcomes of other treatments,” said lead investigator Dr Shadi Hamood in the clinical trial. and deputy director general for internal medicine E at Rambam. He said the findings are particularly encouraging that hospitals are already investigating the use of the treatment for other indications. Bonus reported 10 COVID cases between the ages of 45 and 75. All years had severe symptoms, ninety percent of them still had underlying disease.

The data showed a 40% reduction in lung inflammation with treatment – from 55% to 15% as seen on a chest X-ray. Patients also experienced significant improvements in respiratory function. Significance Blood oxygen saturation increased by 95% and lung function was restored. MesenCure reached almost normal levels after just one month. Meretzki shared lab images of healthy lungs, sick lungs, and lungs treated with MesenCure. Meretzki said, “The treated lungs were almost the same as normal healthy lungs. That’s a complete cure. Most notably, patients were discharged from the hospital after an average period of just one day after the injection, and the company reported no side effects associated with MesenCure. 30 days after treatment All but one survived. The deceased patients did not die from COVID-19. but a preexisting co-morbid COVID-19 patients Many have died due to increased production of inflammatory molecules called cytokines. more than the virus itself Merezky explained When the immune system secretes too much cytokines. what is called “Cytokine storms” can erupt. Such an excessive immune response destroys healthy lung tissue. leading to acute respiratory distress or failure and eventually died Bonus Founded in 2008, the company works with MSCs from its headquarters in Haifa. where the company develops its main products A tissue-engineered bone graft that is also based on MSCs, Meretzki said, MSCs are cells that are “found in all of us. They are responsible for damage control and day-to-day activities.” As the coronavirus outbreak begins in early 2020, Bonus begins investigating the MSC’s potential to mitigate cytokine storms in COVID-19 patients. Phase 2 is scheduled to continue at Rambam and include 50 more patients. However, due to low infection levels in Israel, Bonus has also applied for approval to run the trial in Europe, Meretzki said. Phase II trials should be completed quickly when the remaining patients are full. enroll




Source link